Antibody-drug conjugates--an emerging class of cancer treatment.
Diamantis N, Banerji U. · 2016
Read Antibody-drug conjugates--an emerging class of cancer treatment. by Diamantis N, Banerji U. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4815767.txt.
Description
Nikolaos Diamantis and Udai Banerji review antibody-drug conjugates in the British Journal of Cancer in 2016. A conjugate welds a tumor-seeking antibody to a cell-killing drug. The poison rides to the tumor and spares the rest of the body. Early versions failed. Their drugs were weak, their links shaky, and their targets poor. New linkers and far stronger payloads revived the idea.
Two conjugates had won licenses by the time of the review. One treats breast cancer. One treats lymphoma. A crowd of others filled early trials. The authors lay out what makes one succeed. The target must sit on the tumor and not on healthy tissue. The link must hold in blood and break in the tumor. The payload must work in tiny doses. The focus falls on solid tumors.
Catalog record
| CREATOR | Diamantis N, Banerji U. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |